Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $34.07 Consensus Target Price from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $34.0667.

A number of research analysts recently weighed in on the company. Raymond James Financial raised Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Chardan Capital reduced their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Robert W. Baird lowered their target price on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 18th. Evercore ISI restated an “outperform” rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Finally, Stifel Nicolaus lowered their price target on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, July 31st.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $13.06 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -3.38 and a beta of 1.09. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $35.90. The company’s 50 day simple moving average is $12.41 and its 200 day simple moving average is $11.18.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The stock was purchased at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer directly owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 14.14% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC raised its position in shares of Dyne Therapeutics by 334.3% during the second quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock valued at $1,730,000 after buying an additional 139,896 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in Dyne Therapeutics in the second quarter valued at approximately $420,000. Caxton Associates LLP increased its stake in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the last quarter. Finally, Wasatch Advisors LP increased its position in shares of Dyne Therapeutics by 9.2% during the 2nd quarter. Wasatch Advisors LP now owns 557,937 shares of the company’s stock worth $5,312,000 after purchasing an additional 46,889 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.